ConductScience.org, home

Trial · NCT05500937

Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin

NCT05500937, Phase 2, Phase 3, Unknown, First Affiliated Hospital Xi'an Jiaotong University

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin. Trials, record NCT05500937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05500937

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin
NCT number
NCT05500937
Status
Unknown
Phases
Phase 2, Phase 3
Enrollment
1,000 participants, estimated
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Conditions
Diabetes Mellitus
Interventions
UDCA
First posted
2022-08-15
Last updated
2022-09-28

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChanges of HbA1c12 months after enrollmentChanges of glycosylated hemoglobin after taking ursodeoxycholic acid for half a year
SecondaryConcentration of blood lipid12 months after enrollment
SecondaryConcentration of fasting blood glucose12 months after enrollment
SecondaryConcentration of fasting islets12 months after enrollment
SecondaryConcentration of bile acids12 months after enrollment
SecondaryRate of MACE12 months after enrollment

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05500937

GET https://conductscience.org/api/trials/v1/NCT05500937/registered